REVISED PREDICTIVE BIOMARKER FOR OCRIPLASMIN THERAPY IN VITREOMACULAR TRACTION DISORDERS.
Aged
Biomarkers
Female
Fibrinolysin
/ therapeutic use
Fibrinolytic Agents
/ therapeutic use
Humans
Male
Middle Aged
Peptide Fragments
/ therapeutic use
ROC Curve
Retinal Diseases
/ diagnosis
Retrospective Studies
Tissue Adhesions
/ diagnosis
Visual Acuity
/ physiology
Vitrectomy
Vitreous Body
/ drug effects
Journal
Retina (Philadelphia, Pa.)
ISSN: 1539-2864
Titre abrégé: Retina
Pays: United States
ID NLM: 8309919
Informations de publication
Date de publication:
01 Dec 2021
01 Dec 2021
Historique:
pubmed:
27
6
2021
medline:
15
1
2022
entrez:
26
6
2021
Statut:
ppublish
Résumé
To determine a statistically optimal limit of adhesion size in vitreomacular traction (VMT) syndrome for ocriplasmin treatment. In this retrospective, consecutive, interventional study, we included 106 patients treated with ocriplasmin injection because of VMT between July 2013 and January 2018. A univariate and multivariate risk analysis was performed with grouped factors and continuous factors. We used a receiver operating characteristic curve to measure the prognostic relevance of each continuous factor for therapy success and determined the statistically optimal cutoff value at which specificity and sensitivity are simultaneously maximized. Among the grouped factors, only a phakic lens status showed a highly significant positive influence on the resolution of the VMT. For the continuous factors, only the adhesion diameter before injection was a good predictor of anatomical success. The statistically optimal threshold value for the adhesion size was calculated to be 480 µm. Eyes below this limit had a 6.84-fold better chance of VMT resolution compared with eyes with a larger adhesion diameter. The threshold value of the VMT diameter for ocriplasmin therapy could be statistically defined as 480 µm and may thus be a new quantitative biomarker to predict treatment success.
Identifiants
pubmed: 34173361
doi: 10.1097/IAE.0000000000003244
pii: 00006982-202112000-00017
doi:
Substances chimiques
Biomarkers
0
Fibrinolytic Agents
0
Peptide Fragments
0
microplasmin
7V6HE3DM5A
Fibrinolysin
EC 3.4.21.7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2549-2555Références
Ezra E. Idiopathic full thickness macular hole: natural history and pathogenesis. Br J Ophthalmol 2001;85:102–108.
Johnson MW. Posterior vitreous detachment: evolution and complications of its early stages. Am J Ophthalmol 2010;149:371.e1.
Duker JS, Kaiser PK, Binder S, et al. The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology 2013;120:2611–2619.
Sebag J. Vitreous: the resplendent enigma. Br J Ophthalmol 2009;93:989–991.
Joshi M, Agrawal S, Christoforidis JB. Inflammatory mechanisms of idiopathic epiretinal membrane formation. Mediators Inflamm 2013;2013:192582.
Jackson TL, Nicod E, Angelis A, et al. Pars plana vitrectomy for vitreomacular traction syndrome: a systematic review and metaanalysis of safety and efficacy. Retina 2013;33:2012–2017.
Odrobina D, Michalewska Z, Michalewski J, et al. Long-term evaluation of vitreomacular traction disorder in spectral-domain optical coherence tomography. Retina 2011;31:324–331.
Selver OB, Parlak M, Soylemezoglu ZO, Saatci AO. Spontaneous resolution of vitreomacular traction: a case series. Clin Exp Optom 2013;96:424–427.
Stalmans P. A retrospective cohort study in patients with tractional diseases of the vitreomacular interface (ReCoVit). Graefes Arch Clin Exp Ophthalmol 2016;254:617–628.
Stalmans P, Benz MS, Gandorfer A, et al. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 2012;367:606–615.
Haller JA, Stalmans P, Benz MS, et al. Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials. Ophthalmology 2015;122:117–122.
Khanani AM, Duker JS, Heier JS, et al. Ocriplasmin treatment leads to symptomatic vitreomacular adhesion/vitreomacular traction resolution in the real-world setting: the phase IV ORBIT study. Ophthalmol Retina 2019;3:32–41.
Dugel PU, Tolentino M, Feiner L, et al. Results of the 2-year ocriplasmin for treatment for symptomatic vitreomacular adhesion including macular hole (OASIS) randomized trial. Ophthalmology 2016;123:2232–2247.
Paul C, Heun C, Müller HH, et al. Impact of vitreoretinal interface architecture on successful vitreomacular traction resolution in eyes scheduled for intravitreal ocriplasmin therapy. Retina 2017;37:1252–1260.
Prospero Ponce CM, Stevenson W, Gelman R, et al. Ocriplasmin: who is the best candidate? Clin Ophthalmol 2016;10:485–495.
Paul C, Heun C, Müller HH, et al. Calculating the individual probability of successful ocriplasmin treatment in eyes with VMT syndrome: a multivariable prediction model from the EXPORT study. Br J Ophthalmol 2018;102:1092–1097.
de Smet MD, Gandorfer A, Stalmans P, et al. Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial. Ophthalmology 2009;116:1349–1355.
Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561–577.
Chatziralli I, Theodossiadis G, Xanthopoulou P, et al. Ocriplasmin use for vitreomacular traction and macular hole: a meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications. Graefes Arch Clin Exp Ophthalmol 2016;254:1247–1256.
Jackson TL, Regillo CD, Girach A, Dugel PU. Baseline predictors of vitreomacular adhesion/traction resolution following an intravitreal injection of ocriplasmin. Ophthalmic Surg Lasers Imaging Retina 2016;47:716–723.
Feng HL, Roth DB, Hasan A, et al. Intravitreal ocriplasmin in clinical practice: predictors of success, visual outcomes, and complications. Retina 2018;38:128–136.
Chatziralli I, Theodossiadis G, Parikakis E, et al. Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study. Graefes Arch Clin Exp Ophthalmol 2016;254:223–233.
Johnson MW, Fahim AT, Rao RC. Acute ocriplasmin retinopathy. Retina 2015;35:1055–1058.
Itoh Y, Kaiser PK, Singh RP, et al. Assessment of retinal alterations after intravitreal ocriplasmin with spectral-domain optical coherence tomography. Ophthalmology 2014;121:2506.e2.
Singh RP, Li A, Bedi R, et al. Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome. Br J Ophthalmol 2014;98:356–360.
Fahim AT, Khan NW, Johnson MW. Acute panretinal structural and functional abnormalities after intravitreous ocriplasmin injection. JAMA Ophthalmol 2014;132:484–486.